Related Experiment Video
Updated: Jan 9, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
FAAH and MAGL inhibition: Evolving approaches to treating substance use disorders
Charlie J Maddox1, Francis S Lee2, Anjali M Rajadhyaksha1
1Center for Substance Abuse Research and Department of Neural Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.
Abstract:
Substance use disorder (SUD) remains a critical public health issue characterized by high rates of relapse and limited effective pharmacotherapies, particularly for non-opioid substances. A key challenge in addressing SUD lies in the persistent neuroadaptations within the brain's reward circuitry. The endocannabinoid (eCB) system plays a crucial role in modulating reward and reinforcement processes and is disrupted by chronic drug exposure. Recent work highlights the therapeutic potential of indirectly modulating cannabinoid 1 (CB1) receptor signaling by targeting eCB-metabolizing enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), to restore homeostatic eCB tone. We review and synthesize findings from both genetic and pharmacological studies, highlighting the contributions of FAAH and MAGL across major classes of abused substances and considering their potential as therapeutic targets for SUD treatment.
Related Concept Videos
Drug Abuse and Addiction: Pharmacological Phenomena
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Antidepressant Drugs: MAOIs and Other Agents
CNS Depressants: Alcohol and Nicotine
Alzheimer's Disease: Treatment
Drug Therapy
Antianxiety Medications

